Charlie Teo Foundation
Concentration RiskAbout
The Charlie Teo Foundation is an Australian corporate foundation dedicated to advancing health outcomes. It primarily supports pioneering research into brain tumours and cancer, aiming for breakthroughs in diagnosis and treatment. While based in NSW, its funding extends to international research projects that benefit a broad range of beneficiaries, including youth, children, adults, and the general community.
Giving Philosophy
The foundation is committed to funding cutting-edge, innovative research that promises significant breakthroughs in understanding, diagnosing, and treating brain tumours and cancer. It seeks out pioneering projects globally, valuing scientific advancement and potentially collaborative efforts to achieve its health objectives.
Tips for Applicants
Prospective applicants should demonstrate how their project contributes to pioneering research in brain tumours or cancer, focusing on innovative diagnostic or therapeutic approaches. Highlight potential for significant breakthroughs and broad impact.
Programs & Opportunities (3)
Data-driven research projects targeting adult diffuse gliomas, GBM, and childhood brain cancers
Developing better models, tools, and methodologies for brain cancer research and treatment testing
Supporting unconventional, innovative approaches to brain cancer treatment
Notable Grants
- $1.65M to Prof Matt Dun (University of Newcastle) for I-DIMENSIONS subtyping system for DMG/DIPG
- $1.2M to Prof Joseph Powell (Garvan Institute) for Cancer Genomics
- $1.09M to Prof Peter Fecci (Duke University) for Unshackling the Immune System 2.0
- $1.08M to Prof Joseph Powell (Garvan Institute) for Targeting the Root of Adult Diffuse Gliomas
- $714K to A/Prof Hong Chen (Washington University) for Nasal Drug Delivery to Brainstem for DIPG/DMG
- $609K to Prof Roel Verhaak (Jackson Laboratory) for Evolution of Childhood Brain Cancer
- $595K to Prof Gelareh Zadeh (Mayo Clinic) for Unmasking Hypoxia in GBM
- $477K to Prof Peter Fecci (Duke University) for Unshackling the Immune System
Financial History (5 years)
| Year | Revenue | Expenses | Assets | Surplus |
|---|---|---|---|---|
| 2023 | $3.8M | $2.9M | $10.6M | $895K |
| 2022 | $3.6M | $2.9M | $9.7M | $634K |
| 2021 | $3.8M | $2.6M | $9.4M | $1.2M |
| 2020 | $3.0M | $2.8M | $7.8M | $217K |
| 2019 | $8.5M | $992K | $7.8M | $7.5M |
Community Evidence
External EvidenceIdentity
- GS ID
- AU-ABN-57622041061
- ABN
- 57622041061
- Sector
- health
- Financial Year
- 2023
Focus Areas
Financials
- Revenue
- $3.8M
- Assets
- $10.6M
Method
- Match Confidence
- registry
- Cross-references
- 2 datasets
- Match Key
- ABN
- Relationships
- 17
Matched by Australian Business Number (ABN) — high confidence. This entity was found across multiple government datasets using the same ABN.
Data Sources
Location Intelligence
- Postcode
- 2011
- Locality
- Potts Point - Woolloomooloo
- Remoteness
- Major Cities of Australia
- SEIFA Disadvantage
- Decile 8/10
- LGA
- Sydney
- SA2 Region
- Potts Point - Woolloomooloo
- Entities in Area
- 330